Pure Global
NCT06279572

Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy

Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy: Opportunities for T-Cell Directed Immunotherapy
Mayo Clinic·ClinicalTrials.gov·procedureRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Myeloid Leukemia
Drug/Device/Intervention
Biospecimen Collection
Study type
Observational
Intervention type
procedure
Sponsor & location
Primary sponsor
Mayo Clinic
Location
Scottsdale,Jacksonville,Rochester, United States of America
Timeline & enrollment
Phase
N/A
Start date
Apr 22, 2021
End date
Dec 31, 2026
Enrollment
80 participants
Primary outcome

Immune profile of treatment naive acute myeloid leukemia (AML) patients receiving azacitidine plus venetoclax chemotherapy

Summary

This study investigates the immune profile of patients receiving treatment with venetoclax
 plus azacitidine for acute myeloid leukemia (AML). Studying the information gathered from the
 immune profile from blood and bone marrow samples may help researchers understand the
 associated responses to the treatment of patients undergoing therapy of venetoclax plus
 azacitidine and create future immune based treatment approaches.

ICD-10 classifications
Myeloid leukaemiaAcute myeloblastic leukaemia [AML]Myeloid leukaemia, unspecifiedAcute myelomonocytic leukaemiaAcute myeloid leukaemia with 11q23-abnormality
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06279572
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06279572 through Pure Global AI's free database. This phase not specified trial is sponsored by Mayo Clinic and is currently Recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.